** Rare disease diagnostics company GeneDx WGS.O shares up ~8.9% at $92.8
** Piper Sandler initiates coverage on WGS with "overweight" rating, saying the company has a unique first-mover advantage in a fast-growing and expanding market in rare disease testing
** WGS has high penetration rates among key clinician types, including an 80% market share among genetics experts and 13% among pediatric neurologists - brokerage
** Piper Sandler sets PT at $110, implying a ~29% upside to stock's last close
** Six of seven brokerages rate the stock "buy" or higher, one "hold"; median PT is $105 - data compiled by LSEG
** Including session's moves, stock up ~20.8% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.